Medication info

Trajenta Duo Tablets 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
White Life Sciences Co., Ltd.
Appearance
Bright orange film-coated oval tablets with both sides convex
Packaging
60 tablets (10 tablets/Alu-Alu X 6)
Approval status
Active

MFDS item code 202201893 · Approved 2022.05.10

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
White Life Sciences Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to assist blood sugar control in patients with type 2 diabetes using a combination of linagliptin and metformin. It effectively manages blood sugar levels when combined with dietary control and exercise therapy, improving diabetes management.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to contain linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication helps to control blood sugar levels. However, one of its active ingredients, metformin, can cause a serious side effect known as lactic acidosis, which requires caution. Lactic acidosis may lead to the excessive accumulation of lactic acid in the body, causing severe symptoms, and if untreated, can be life-threatening. Therefore, it should not be used in patients with impaired kidney function, severe liver disease, heart failure, or other unstable conditions such as acute infections. Additionally, pregnant or breastfeeding women, as well as individuals with acute alcohol intoxication should not take this medication. During treatment, hypoglycemic symptoms may occur, so blood sugar changes must be closely monitored, especially when used with insulin or sulfonylureas. Elderly patients with decreased kidney function or those taking other medications that may affect kidney function should undergo regular kidney function tests. When undergoing acute surgery or radiographic examinations using contrast agents, this medication should be temporarily discontinued and restarted only after kidney function has recovered. Patients taking this medication may experience pancreatitis or skin blistering disorders, so any abdominal pain or skin abnormalities should prompt immediate consultation with a physician. Metformin may lower vitamin B12 levels, so regular testing for vitamin B12 is advisable during prolonged use. This medication is not recommended for children and patients under 10 years of age, and dosage adjustments should be made based on kidney function for elderly patients. Finally, it is important to store this medication out of the reach of children and to avoid moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 reduction and deficiency
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 130 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and debilitating arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • viral upper respiratory infection
  • upper respiratory infection
  • gastroenteritis
  • pneumonia
  • shingles
  • cystitis
  • hyperglycemia
  • dizziness
  • headache
  • drowsiness
  • chest discomfort
  • weakness
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • osteoarthritis
  • limb pain
  • pruritus
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • epigastric pain
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • diabetic neuropathy
  • drowsiness
  • confusion
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture and should be kept at a safe temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Bright orange film-coated oval tablets with both sides convex

Package unit

60 tablets (10 tablets/Alu-Alu X 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.